BRUSSELS, March 1, 2012 /PRNewswire/ -- CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).
One of the primary criteria for the award is a demonstrated commitment to providing access to therapies for people with rare diseases. The award was presented yesterday at the first EURORDIS Gala Dinner in the Hotel Le Plaza. "Solidarity," the theme of 2012 Rare Disease Day, focuses on the importance and the need for collaboration in the field of rare diseases.
"CSL Behring is honored and delighted to receive a 2012 EURORDIS Award," said Senior Vice President of Public Affairs Dennis Jackman. "This award is a reflection of our commitment to providing safe and effective therapies to improve the lives of patients with rare and serious medical conditions. CSL Behring's commitment is further demonstrated in the company's growing investment in research and development, which has added to an extensive rare disease product portfolio, and in advanced manufacturing facilities and patient support."
CSL Behring received the National Organization for Rare Disorders 2011 Corporate Award for new treatments for rare diseases brought to market in the U.S.
EURORDIS is a non-governmental, patient-driven alliance of patient organisations and individuals active in the field of rare diseases, dedicated to improving the quality of life of all people living with rare diseases in Europe.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com or view CSL Limited's Corporate Responsibility Report.
Manager, Corporate Communications
|SOURCE CSL Behring|
Copyright©2010 PR Newswire.
All rights reserved